JP2003522514A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522514A5
JP2003522514A5 JP2000520572A JP2000520572A JP2003522514A5 JP 2003522514 A5 JP2003522514 A5 JP 2003522514A5 JP 2000520572 A JP2000520572 A JP 2000520572A JP 2000520572 A JP2000520572 A JP 2000520572A JP 2003522514 A5 JP2003522514 A5 JP 2003522514A5
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
acid molecule
seq
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000520572A
Other languages
English (en)
Japanese (ja)
Other versions
JP4472866B2 (ja
JP2003522514A (ja
Filing date
Publication date
Priority claimed from GBGB9723516.2A external-priority patent/GB9723516D0/en
Priority claimed from GBGB9724190.5A external-priority patent/GB9724190D0/en
Priority claimed from GBGB9724386.9A external-priority patent/GB9724386D0/en
Priority claimed from GBGB9725158.1A external-priority patent/GB9725158D0/en
Priority claimed from GBGB9726147.3A external-priority patent/GB9726147D0/en
Priority claimed from GBGB9800759.4A external-priority patent/GB9800759D0/en
Priority claimed from GBGB9819016.8A external-priority patent/GB9819016D0/en
Application filed filed Critical
Priority claimed from PCT/IB1998/001665 external-priority patent/WO1999024578A2/en
Publication of JP2003522514A publication Critical patent/JP2003522514A/ja
Publication of JP2003522514A5 publication Critical patent/JP2003522514A5/ja
Publication of JP4472866B2 publication Critical patent/JP4472866B2/ja
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000520572A 1997-11-06 1998-10-09 ナイセリア抗原 Expired - Fee Related JP4472866B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GBGB9723516.2A GB9723516D0 (enExample) 1997-11-06 1997-11-06
GB9723516.2 1997-11-06
GB9724190.5 1997-11-14
GBGB9724190.5A GB9724190D0 (enExample) 1997-11-14 1997-11-14
GBGB9724386.9A GB9724386D0 (enExample) 1997-11-18 1997-11-18
GB9724386.9 1997-11-18
GB9725158.1 1997-11-27
GBGB9725158.1A GB9725158D0 (enExample) 1997-11-27 1997-11-27
GB9726147.3 1997-12-10
GBGB9726147.3A GB9726147D0 (en) 1997-12-10 1997-12-10 Antigens
GBGB9800759.4A GB9800759D0 (enExample) 1998-01-14 1998-01-14
GB9800759.4 1998-01-14
GB9819016.8 1998-09-01
GBGB9819016.8A GB9819016D0 (enExample) 1998-09-01 1998-09-01
PCT/IB1998/001665 WO1999024578A2 (en) 1997-11-06 1998-10-09 Neisserial antigens

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005290551A Division JP2006089488A (ja) 1997-11-06 2005-10-03 ナイセリア抗原
JP2009245980A Division JP2010046089A (ja) 1997-11-06 2009-10-26 ナイセリア抗原

Publications (3)

Publication Number Publication Date
JP2003522514A JP2003522514A (ja) 2003-07-29
JP2003522514A5 true JP2003522514A5 (enExample) 2009-04-30
JP4472866B2 JP4472866B2 (ja) 2010-06-02

Family

ID=27562941

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000520572A Expired - Fee Related JP4472866B2 (ja) 1997-11-06 1998-10-09 ナイセリア抗原
JP2005290551A Withdrawn JP2006089488A (ja) 1997-11-06 2005-10-03 ナイセリア抗原
JP2009245980A Withdrawn JP2010046089A (ja) 1997-11-06 2009-10-26 ナイセリア抗原

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2005290551A Withdrawn JP2006089488A (ja) 1997-11-06 2005-10-03 ナイセリア抗原
JP2009245980A Withdrawn JP2010046089A (ja) 1997-11-06 2009-10-26 ナイセリア抗原

Country Status (10)

Country Link
EP (3) EP1900818A3 (enExample)
JP (3) JP4472866B2 (enExample)
CN (1) CN1263854C (enExample)
AT (1) ATE476508T1 (enExample)
AU (1) AU9363798A (enExample)
BR (1) BR9813930A (enExample)
CA (2) CA2308606A1 (enExample)
CY (1) CY1110880T1 (enExample)
DE (1) DE69841807D1 (enExample)
WO (1) WO1999024578A2 (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
AUPP083997A0 (en) 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
EP2261341A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9814902D0 (en) * 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
JP2004537956A (ja) 1999-01-22 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
AU3164600A (en) 1999-03-12 2000-10-04 Smithkline Beecham Biologicals (Sa) Novel compounds
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9918003D0 (en) * 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
DE60044005D1 (de) 1999-11-29 2010-04-22 Novartis Vaccines & Diagnostic 85 kDa Antigen von Neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
IL150822A0 (en) 2000-01-25 2003-02-12 Univ Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
CN101139590B (zh) * 2000-02-28 2012-07-18 启龙股份公司 奈瑟球菌蛋白质的杂交表达
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
US6830898B2 (en) * 2000-08-24 2004-12-14 Omnigene Bioproducts, Inc. Microorganisms and assays for the identification of antibiotics
AU2002211999A1 (en) 2000-10-02 2002-04-15 Id Biomedical Corporation Haemophilus influenzae antigens and corresponding DNA fragments
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2002060936A2 (en) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109289D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Novel compounds
ES2316563T3 (es) 2001-05-15 2009-04-16 Id Biomedical Corporation Antigenos de moraxella (branhamella) catarrhalis.
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MXPA04000653A (es) 2001-07-27 2004-11-22 Chiron Srl Adhesinas de meningococcus nada, app y orf 40.
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CN100354297C (zh) * 2001-10-03 2007-12-12 希龙公司 辅助的脑膜炎球菌组合物
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
EP1531796B1 (en) 2002-02-20 2016-09-28 GlaxoSmithKline Biologicals SA Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
JP2006519605A (ja) * 2003-03-06 2006-08-31 チルドレンズ ホスピタル， インコーポレイテッド 類型不能ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅの中耳炎単離株の遺伝子
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
CA2612240A1 (en) 2005-06-16 2006-12-28 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
CN101355960A (zh) 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007110602A1 (en) * 2006-03-28 2007-10-04 The University Of Nottingham Immunogenic compositions
WO2008001224A2 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
AU2009309416B2 (en) 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method
JP2012508586A (ja) 2008-11-14 2012-04-12 ジェン−プローブ・インコーポレーテッド カンピロバクター属（Ｃａｍｐｙｌｏｂａｃｔｅｒ）核酸を検出するための組成物、キットおよび方法
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
WO2011127360A1 (en) 2010-04-08 2011-10-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
MX2013000250A (es) * 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012095684A1 (en) * 2011-01-10 2012-07-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for the screening of substances useful for the prevention and treatment of neisseria infections
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
US8986710B2 (en) 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP3420355A1 (en) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica GmbH Method for the immobilization of biomolecules
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
IL276608B2 (en) 2018-02-12 2024-04-01 Inimmune Corp Toll-like receptor ligands
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2023547676A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス ＤＮＡペイロードをアクネ菌集団へとｉｎ ｓｉｔｕ送達するためのファージ由来粒子
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
EP0063953A3 (en) 1981-04-29 1983-10-19 Biogen N.V. Bacillus cloning vectors, recombinant dna molecules, bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0196056B1 (en) 1985-03-28 1991-05-22 Chiron Corporation Improved expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
ATE110111T1 (de) 1986-05-02 1994-09-15 Gist Brocades Nv Sekretionssignal-selektionsvektoren für extrazelluläre proteinsynthese in bazillen.
ATE247708T1 (de) 1986-10-02 2003-09-15 Massachusetts Inst Technology Verfahren zur regulierung der metabolischen stabilität von proteinen
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
CA1304020C (en) 1987-03-23 1992-06-23 Meher H. Irani High level expression in yeast
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
IE62868B1 (en) 1987-11-18 1995-03-08 Chiron Corp Hepatitis C virus
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
JPH03504079A (ja) 1988-03-21 1991-09-12 カイロン　コーポレイション 組換えレトロウィルス
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0432216A1 (en) 1988-09-01 1991-06-19 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NL9021328A (nl) 1989-08-15 1992-06-01 Pasminco Australia Ltd Werkwijze en inrichting voor de absorptie van zinkdamp in gesmolten lood.
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
JPH06500923A (ja) 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
JP3337214B2 (ja) 1990-12-20 2002-10-21 アーチ・ディベロップメント・コーポレーション 電離線による遺伝子発現の調節
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
WO1993014778A1 (en) 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FI951404A7 (fi) 1992-09-25 1995-03-24 Rhone Poulenc Rorer Sa Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän , erityisesti aivojen, soluihin
EP1321526A3 (en) 1992-11-18 2003-07-02 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
WO1994028157A1 (en) 1993-05-26 1994-12-08 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Fusion proteins containing adeno-associated virus rep protein and bacterial protein
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
JPH09505561A (ja) 1993-10-01 1997-06-03 アメリカ合衆国 神経系の遺伝子治療
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
JPH11505128A (ja) 1995-05-22 1999-05-18 カイロン コーポレイション キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
DE19534579C2 (de) * 1995-09-18 2000-06-08 Max Planck Gesellschaft Nucleinsäure-Moleküle codierend Proteine, die die Adhäsion von Neisseria-Zellen an humane Zellen vermitteln
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
EP2261341A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US9714465B2 (en) 2008-12-01 2017-07-25 Applied Materials, Inc. Gas distribution blocker apparatus

Similar Documents

Publication Publication Date Title
JP2003522514A5 (enExample)
JP2004511201A5 (enExample)
JP2002524024A5 (enExample)
JP2002535956A5 (enExample)
JP2002503495A5 (enExample)
CA2289914A1 (en) Igf-1 receptor interacting proteins (iips), genes coding therefor and uses thereof
EP1162206A3 (en) Peptide nucleic acids
JP2003525623A5 (enExample)
EP1808180A3 (en) Modified GP 100 and uses thereof
WO2003020932A1 (en) Novel secretory proteins and dna thereof
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
JP2004194588A5 (enExample)
JP2003509018A5 (enExample)
WO1998006841A3 (en) Two human nsp-like proteins
WO1999054349A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
DE60041042D1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
JPH10210974A5 (enExample)
WO2003031459A3 (de) Modulation der expression stat-1-abhängiger gene
JP2004516801A5 (enExample)
JP2004500045A5 (enExample)
CA2448347A1 (en) Novel human hydroxylases and polynucleotides encoding the same
WO2003022039A1 (fr) Procede permettant de conferer une resistance a un virus au moyen d'une proteine vegetale se liant a une proteine de transport de virus vegetal
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
WO2000040607A3 (en) Tiam2 (t-cell lymphoma invasion and metastasis 2) nucleotide exchange factor